Patents by Inventor Yanmei Lu
Yanmei Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230384310Abstract: The disclosure relates to total antibody assays, including screening assays and confirmatory assays, for the detection of anti-AAV (e.g. anti-AAV6) antibodies in a subject as it relates to pre- and post-treatment total antibody levels. The disclosure also relates to methods of treating a subject with a gene therapy comprising a rAAV (e.g. rAAV6) vector.Type: ApplicationFiled: October 1, 2021Publication date: November 30, 2023Inventors: Jing Hu, Yanmei Lu
-
Patent number: 7243112Abstract: This invention provides an advanced platform for the analysis of biological data that emphasizes pathway mapping and relationship inference based upon data acquired from multiple diverse sources. The platform employs a bioinformatic system that integrates data from the diverse sources, connecting related genes and proteins and inferring biological functions in the context of global cellular processes.Type: GrantFiled: June 14, 2002Date of Patent: July 10, 2007Assignee: Rigel Pharmaceuticals, Inc.Inventors: Kunbin Qu, Nan Lin, Yanmei Lu, Donald G. Payan
-
Patent number: 6891022Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targents for the diagnosis and/or treatment (including prevention) of certain tumors (e.g., cancer) and may act as predictors of the prognosis of tumor treatment.Type: GrantFiled: April 23, 1999Date of Patent: May 10, 2005Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Publication number: 20040162852Abstract: This invention provides an advanced platform for the analysis of biological data that emphasizes pathway mapping and relationship inference based upon data acquired from multiple diverse sources (102). The platform employs a bioinformatic system (100) that integrates data from the diverse sources (102), connecting related genes and proteins and inferring biological functions (108) in the context of global cellular processes.Type: ApplicationFiled: December 11, 2003Publication date: August 19, 2004Inventors: Kunbin Qu, Nan Lin, Yanmei Lu, Donald G. Payan
-
Publication number: 20030191283Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targents for the diagnosis and/or treatment (including prevention) of certain tumors (e.g., cancer) and may act as predictors of the prognosis of tumor treatment.Type: ApplicationFiled: January 31, 2002Publication date: October 9, 2003Applicant: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Publication number: 20020147322Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targents for the diagnosis and/or treatment (including prevention) of certain tumors (e.g., cancer) and may act as predictors of the prognosis of tumor treatment.Type: ApplicationFiled: August 15, 2001Publication date: October 10, 2002Applicant: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6326482Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplasfic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain tumors (e.g. cancer) and may act as predictors of the prognosis of tumor treatment.Type: GrantFiled: August 9, 1999Date of Patent: December 4, 2001Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6051690Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs). oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to Nsp1, Nsp2 and Nsp3.Type: GrantFiled: April 23, 1998Date of Patent: April 18, 2000Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6051403Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to Nsp1, Nsp2 and Nsp3.Type: GrantFiled: August 4, 1999Date of Patent: April 18, 2000Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu